Dx & Vx Co., Ltd. (KOSDAQ:180400)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,610.00
-210.00 (-4.36%)
At close: Feb 27, 2026
174.90%
Market Cap 453.76B
Revenue (ttm) 29.47B
Net Income (ttm) -50.92B
Shares Out 98.43M
EPS (ttm) -1,033.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 299,179
Average Volume 541,457
Open 4,820.00
Previous Close 4,820.00
Day's Range 4,550.00 - 4,870.00
52-Week Range 1,319.00 - 5,280.00
Beta 0.29
RSI 59.25
Earnings Date Nov 14, 2025

About Dx & Vx

Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis ... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2001
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 180400
Full Company Profile

Financial Performance

In 2024, Dx & Vx's revenue was 33.95 billion, a decrease of -17.69% compared to the previous year's 41.24 billion. Losses were -47.03 billion, 71.1% more than in 2023.

Financial Statements

News

There is no news available yet.